Brand Name

Portrazza

Generic Name
Necitumumab
View Brand Information
FDA approval date: November 24, 2015
Classification: Epidermal Growth Factor Receptor Antagonist
Form: Solution

What is Portrazza (Necitumumab)?

PORTRAZZA™ is an epidermal growth factor receptor antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function.
Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function.
Journal: Cancers
Published: December 22, 2025
Detection and warning of drug-induced hypomagnesemia: a pharmacovigilance study of the FDA Adverse Event Reporting System.
Detection and warning of drug-induced hypomagnesemia: a pharmacovigilance study of the FDA Adverse Event Reporting System.
Journal: Magnesium research
Published: September 26, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.
Journal: JCO precision oncology
Published: June 04, 2025
View All Latest Advances